In real-world patients with subjective cognitive complaint (SCC) and mild cognitive impairment (MCI), blood biomarkers for AD and neurodegeneration correlate with underlying pathology, but add little to the 5-year dementia risk prediction models.
Why this matters
Blood biomarkers for AD classification have been widely used in clinical trials, generating consistent results. Their utilization in real-world patient populations is yet to be validated.
These results will facilitate patient selection for further biomarker testing in a clinical setting.